Brtnikova, Michaela
Studts, Jamie L.
Robertson, Elise
Dickinson, L. Miriam
Carroll, Jennifer K.
Krist, Alex H.
Cronin, John T.
Glasgow, Russell E.
Funding for this research was provided by:
NCI Implementation Science Center grant (P50CA244688, P50CA244688, P50CA244688, P50CA244688, P50CA244688, P50CA244688, P50CA244688)
NCI Comprehensive Cancer Center grant (P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934)
Article History
Received: 18 March 2022
Accepted: 1 September 2022
First Online: 9 September 2022
Declarations
:
: This study was approved as expedited by the Colorado Multiple Institutional Review Board, protocol number 19–1706. Written participant consent has been waived per Colorado Multiple Institutional Review Board. All methods were carried out in accordance with relevant guidelines and regulations of the Colorado Multiple Institutional Review Board.
: Not applicable.
: Dr. Studts has provided compensated consultation to the J&J Lung Cancer Initiative, uncompensated consultation to Genentech, and serves on a Medical Advisory Board for the Lung Ambition Alliance, supported by AstraZeneca. None of the other authors have conflict of interest.